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The aim of this study was to analyze scientific production concerning the validation and cultural adaptation of
quality of life evaluation instruments for patients with melasma and to offer a critical reflection on these
methods. A literature review was performed based on a search of the Web of Science, Bireme, PubMed, Elsevier
Scopus, and Google Scholar databases. All published articles from indexed periodicals in these electronic data-
bases up to December 2015 were included. Eight articles were identified, of which only one (12.5%) referred
to the development and validation of a specific instrument for evaluation of the quality of life of melasma
patients. An additional six articles (75%) referred to transcultural adjustment and validation of the same
instrument in other languages, and another (12.5%) article reported the development of a generic instrument
for evaluation of quality of life in patients with pigment disorders. This review revealed only one specific instru-
ment developed and validated in different cultures. Despite being widely used, this instrument did not follow
the classic construction steps for psychometric instruments, which paves the way for future studies to develop
novel instruments.
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’ INTRODUCTION
Melasma is a recurrent chronic change in pigmentation
characterized by asymptomatic, symmetrical, hyperpigmen-
ted macules in the skin due to local hypermelanogenesis that
affects millions of people worldwide (1).
Melasma mainly affects women of fertile age in photo-
exposed areas, especially the face (2). Hispanic and Asiatic
populations have a higher incidence (3), as do populations
living in areas with strong solar radiation, such as India,
Pakistan, the Middle East, and the Mediterranean (4).
The high level of population miscegenation in Brazil and
its predominantly tropical climate favor the development
of the disease in the country. When considering the different
regions and their ethnic compositions, the authors estimate
that between 15 and 35% of adult Brazilian women are
affected by melasma (5).
Although few population studies in Brazil have evaluated
the prevalence of the disease, pigmented dermatosis is the
third most common cause of consultations in dermatology
clinics (8.4%), with variation based on the age group, gender
and region of the country (6). For instance, the prevalence of
melasma was 22% in a study with adults in public institu-
tions from inland Brazil (5).
Treatment of melisma as a chronic disease results in the
use of only palliative treatments. Because it only occurs in
visible areas, melasma can have a significant impact on the
quality of life. However, quality of life is a subjective concept
linked to the perspective of each individual.
Psychometric questionnaires for the evaluation of health-
related quality of life (HRQoL) can be divided into two types
(generic and specific). The generic instruments are multidi-
mensional and are developed to evaluate the impact caused
by a disease in various aspects of life. The disadvantage of
these instruments is that they are not sensitive for the detec-
tion of specific aspects of the impact on the quality of life
inflicted by a particular disease (7).
Specific instruments can also be multidimensional and can
be used to evaluate particular aspects of the quality of life
of a specific individual, with an emphasis on symptoms,
incapacities, or limitations related to a specific ailment. The
disadvantage of these instruments is the difficulty in under-
standing the general phenomenon (7).
In this context, despite the relevance of evaluating quality
of life in patients with melasma for clinical practice and treat-
ment, no recent studies have permitted integration through
reviews of the measurement instruments available in the
literature.
Health assistance providers in Brazil use a single translated
and validated instrument, which does not always incorpo-
rate regional specifics. This investigation was instigated in
view of the need to investigate the most used instruments to
evaluate the quality of life in patients with melasma and to
contribute to the development of future research for nursing
in this area.DOI: 10.6061/clinics/2018/e65
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The objective of this study was to understand and analyze
scientific production related to quality of life evaluation
instruments for patients with melasma.
’ METHOD
An integrative review study was performed using the
following steps: identification of the hypothesis or guiding
question, followed by a search using descriptors or key-
words; establishing inclusion and exclusion criteria for sample
selection; study categorization; evaluation of studies; discus-
sion and interpretation of the results; presentation of the
integrative review and knowledge synthesis (8).
To guide an integrative review, the following question was
formulated: ‘‘How many instruments are available in the
literature to evaluate quality of life in patients with melasma?’’
The inclusion criteria for this integrative review were as
follows: articles published before December 31, 2015; articles
indexed as validation studies in the study databases; and
articles published in Portuguese, English, or Spanish.
Articles were identified in the Web of Science, Bireme,
PubMed (PMC), Scopus, and Google Scholar databases using
the keywords melasma, quality of life, development and
validation studies through search strategies using the AND
Boolean operator.
The information was summarized and organized using
an instrument constructed for this purpose by taking into
consideration the following aspects: title; author; periodical;
year of publication; instrument used to evaluate the quality
of life; database; sample; validity; and internal consistency
(Cronbach’s alpha).
The results were presented, and the obtained data were
discussed descriptively to reach the objective of this method.
After reading and analyzing the studies, we opted to group
them into two categories as follows: specific instruments to
evaluate the quality of life related to melasma (QoLRM) and
specific instruments to evaluate the QoLRM validated and
adapted to other cultures.
’ RESULTS
The search identified 509 articles. A total of 501 articles
were excluded after reading the abstracts, because they did
not meet the established criteria. In other words, they did not
address cultural and language development and adaptation.
Thus, the final sample consisted of eight articles, as shown
in Figure 1.
All of the articles were configured as methodological
investigation studies, in which transverse delineation pre-
dominated to meet the proposed objectives.
The articles were published during the period between
1999 and 2014, as shown in Table 1.
The studies were performed in the United States (12.5%),
South America (37.5%), Western Europe (25%), and Asia
(25%). The majority of the periodicals were in the area of
dermatology, with a mean impact factor of 3.6 (1.76-5.0).
In addition to the specific instrument used to evaluate the
quality of life in melasma patients (MelasQoL), two articles
(25%) concomitantly used the WHO Quality of Life – Brief
(WHOQOL-Bref), and one article (12.5%) used one a non-
cited Spanish questionnaire on the quality of life. Two other
articles (25%) used specific instruments to evaluate the
quality of life in dermatology, and three articles (37.5%) did
not refer to the use of any other instrument.
Specific instrument to evaluate the quality of life
related to melasma (QoLRM)
This review only identified one specific instrument for
evaluation of the QoLRM. In 2003, a researcher at the
University of Virginia developed and validated the Melas-
QoL (Melasma Quality of Life Scale) (9), which is an instru-
ment that specifically contains ten items to evaluate the
effect of melasma on the emotional state, social relationships,
and daily activities. This instrument was developed from
compiling seven questions from the SKINDEX-16 question-
naire (Quality of Life Index related to skin diseases) and
three items from an unspecified questionnaire about changes
in skin color. Thus, the instrument was not based on classical
psychometric steps or the symbolic perceptions of the
patients (Figure 2).
Figure 1 - Flow diagram representing the article selection process.
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The English version of the MelasQoL displayed high
internal consistency, validity, and discriminatory power
compared to the general questionnaires for evaluating
quality of life in dermatology [the DLQI (Dermatology
Life Quality Index) (10) and SKINDEX-16 (11)]. Although
the authors state that the MelaQoL is one dimensional,
statistical data show that this instrument is multidi-
mensional.
Table 1 - List of the articles included in this literature review. Botucatu, SP, Brazil, 2015.
N Title Author Periodical Year Instruments Database
1 Development and validation of a
quality of life measurement for
chronic skin disorders in French
Grob JJ, Auquier P, Martin S,
Lanc¸on C, Bonerandi JJ.
Dermatology / 1999 SF-36
VQ-Dermato
Google Scholar
2 Development and validation of a
health-related quality of life
instrument for women with
melasma
Balkrishnan R, McMichael
AJ, Camacho FT, Saltzberg F,
Housman TS, Grummer S,
et al.








3 Validation of a melasma quality of
life questionnaire for Brazilian
Portuguese language: the
MelasQoL-BP study and
improvement of QoL of melasma
patients after triple combination
therapy
Cestari TF, Hexsel D, Viegas
ML, Azulay L, Hassun K,
Almeida AR, et al.




4 Melasma in Latina patients: cross-
cultural adaptation and validation
of a quality-of-life questionnaire in
Spanish
Dominguez AR, Balkrishnan
R, Ellsey AR, Pandya AG.
J Am Acad Dermatol/ 2006 MelasQoL
Instrument for quality
of life in Spanish
MASI
Google Scholar
5 Translation and cultural adaptation
to Portuguese of a quality of life
questionnaire for patients with
melasma
Cestari TF, Balkrishann R,
Weber MB, Prati C,
Menegon DB, Mazzotti NG,
et al.
Med Cutan Iber Lat Am/ 2006 MelasQoL
Not cited
Google Scholar
6 Validation of a melasma quality of
life questionnaire for the Turkish
language: the MelasQoL-TR study
Dogramaci AC, Havlucu DY,
Inandi T, Balkrishann R.




7 Validation of the MELASQoL quality
of life index in a group of
Colombian melasma patients
Go´mez LJ Repository.urosario.edu.co MelasQoL
Not cited
Google Scholar
8 Reliability and validity of the Arabic
version of the Melasma Quality of
Life questionnaire: MELASQoL-A)
study
Abou-Taleb DA, Youssef EM,
Ibrahim AK, Moubasher AE.




Figure 2 - MelasQoL Questionnaire.
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From this perspective, the MelasQoL is a valid and reliable
instrument that can be used to evaluate the repercussions
of melasma on the patient’s quality of life.
Specific instrument to evaluate the QoLRM
validated and adapted to other cultures
Transcultural adaptation of the original questionnaire
into Spanish (12) was performed using directives established
in the literature. The pre-test was performed on a group of
30 patients and then applied to 112 sequential patients at
a community outpatient clinic. The level of melasma was
determined by clinical examination using the Melasma Area
and Severity Index (MASI). Other authors have concluded
that this instrument is a semantic translation equivalent to
the original English version of the MelasQoL.
Validation of the Brazilian Portuguese version of the
MelasQoL (13) was performed using a multicenter study
with 300 individuals from five different Brazilian geogra-
phical regions. The analysis revealed an important impact of
the disease in relation to skin appearance, since 65% of the
participants referred to being uncomfortable with blemishes
all or the majority of the time, 55% felt frustrated, and 57%
were ill at ease due to the condition of their skin.
This study concomitantly used both the MASI and theWorld
Health Organization instrument for quality of life evaluation
(WHOQOL-BREF) to respectively evaluate the melasma
severity and quality of life. The instrument displayed signifi-
cant internal consistency (Cronbach’s alpha=0.92; po0.01)
and good correlation with the MASI scores. The results of
this study demonstrated that the MelasQoL-BP was a valid
instrument that could be used to evaluate quality of life in
Brazilian patients with melasma (13).
The validation process for the Turkish version of the
MelasQoL (MelasQoL-Tr) (14) included 114 melasma patients.
The MASI, MelasQoL-Tr, and WHOQOL-BREF were used
to evaluate the melasma severity and quality of life. The
reliability and validity of the MelasQoL-Tr demonstrated that
this instrument was valid and reliable for evaluation of the
quality of life in Turkish patients with melasma.
During the translation and validation process for the Arabic
version (15), 65 female patients participated in the study
using the MASI. Internal consistency was tested for all ten
items on the MelasQoL scale (Arabic version) with excellent
results. An intra-class coefficient of correlation (ICC) of 0.914
and a Cronbach’s alpha of 0.94 indicated high reliability for
the Arabic version. A positive correlation was found between
the MelasQoL scale and MASI scores (r=0.41). The analysis
revealed that the Arabic version of the MelasQoL scale was a
reliable and valid measure for evaluation of the quality of
life in Arabic patients with melasma.
The validation performed in Colombia included 80 women
and obtained the following validation criteria: internal
consistency with Cronbach=0.88; validity with rs=0.70,
po0.001; and reproducibility with intra-class coefficient of
correlation=0.959 (CI 95%: 0.986, po0.001), the main
conclusion was that the scale was a good indicator of the
quality of life in the studied group of Colombian women
with melasma (16).
Finally, all of the above cited instruments began with
the translation and cultural adaptation of the original Melas-
QoL (9) instrument, and the objective of the authors was to
develop and validate a specific instrument for the disease to
identify the dimensions of life most affected by melasma.
The other instruments identified in the articles and used
together in the studies, such as the DLQI (Dermatology Life
Quality Index) and SKINDEX-16, were not included in the
analysis, because they were considered specific instruments
for evaluating the quality of life in general dermatology. Some
authors also used generic instruments, such as the SF-12 and
WHOQOL.
Table 2 summarizes the publications related to the valida-
tion and transcultural adaptation of the MelasQoL.
’ DISCUSSION
Although asymptomatic, melasma affects exposed areas,
such as the face, mainly in women of fertile age, which maxi-
mizes its impact on body image and interpersonal relation-
ships and thus potentially interferes with the perception of
quality of life.
The literature has shown the need to look more deeply at
patients with dermatological problems that are often neglected
as not being life threatening (17). In dermatology, health
professionals must evaluate the quality of life of those
affected by skin pigmentation disorders, because many
complaints and problems can be resolved or treated when
individuals feel that they are listened to, understood, and
respected (18).
The results of this study identified only one specific instru-
ment in the literature for evaluation of the quality of life
in patients with melasma (MelasQoL); this instrument has
been translated and validated for other cultures. However,
the development of this instrument did not follow the classic
steps of psychometry for the construction and validation of
a psychometric instrument, since the selection process was
based on the composition of other questionnaires and not on
the individual symbolic perceptions of the patients.
Table 2 - Publications in relation to validation and transcultural adaptation works of MelasQoL. Botucatu, SP, Brazil, 2015.
N Country Sample Internal Consistency
Cronbach’s Alpha
Reliability
1 United States 102 0.95 The MelasQoL scores were highly correlated with the other QoLRS measurements,
highlighting that the instrument was reliable.
2 Brazil 147 0.89 Reliability analysis revealed a satisfactory result.
3 Brazil 300 0.91 Analysis of MelasQoL-BP demonstrated the disease had an important impact on the QoL.
4 Spain 112 0.91 No significant differences were found between the domain coefficients. Many of these QoLRS
domains were identified as significantly affected by melasma.
5 Turkey 114 0.88 Correlation of the MelasQoL-Tr with the WhoQoL-Bref and MASI demonstrated that the
instrument was reliable.
6 Arabia 65 0.94 Internal Consistency for the 10 items in the Arabic version of the MELASQoL-A
questionnaire was excellent; ICC=0.914 and Cronbach’s alpha=0.944, indicating high reliability.
7 Colombia 80 0.88 ICC=0.959, obtaining good indices for evaluating the quality of life in Colombian women.
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One point is that this instrument stimulates questioning
related to instrument reliability, even though the original
version in English presented high internal consistency, validity,
and discriminatory power compared to other questionnaires.
Another point to be considered is that the validation process
has only been applied in women.
Additionally, the latent factorial structure and dimension-
ality of the MelasQoL have not been adequately explored in
development and validation studies. At this stage, no studies
have examined construct stability (test-retest) (9).
Furthermore, the high level of item subjectivity and the
number of reply options stimulate criticism regarding possible
difficulty in understanding by the patients, the dissociative
behavior of item scores from a lack of evaluation of the
impact of the disease in personal relationships and the low
correlation with clinical scores, which could render the results
poorly representative. Strikingly, the instrument does not
rank the impact on the quality of life or even categorize the
severity based on score behavior. The temporal stability of
the questionnaire was not measured, and the dimensionality
was not adequately explored (9).
Another interesting point is that the MelasQoL uses a small
number of items to represent psychological aspects linked
to melasma compared to its impact on social relationships,
leisure, profession, and physical appearance. Despite the sim-
plicity and applicability of an instrument with only ten items,
representation of the measurement of feelings and perceptions
linked to self-esteemwas less important to authors, which poten-
tially compromised instrument precision. Furthermore, items
related to emotional wellbeing have been identified as having
a high magnitude in quality of life studies on melasma (19-21).
This review identified only one specific instrument for
evaluation of the quality of life in patients with melasma,
which was developed and validated for different cultures.
However, despite being very widespread, the instrument did
not follow the classic construction stages for psychometric
instruments, which supported the premise of its fragility. The
other selected articles were related to the translation and
validation processes to other cultures.
This study contributes to the field, because it shows a gap
in this area of understanding and paves the way for the
development and validation of other instruments for eval-
uating quality of life related to melasma.
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